Analysts expect Relmada Therapeutics, Inc. (NASDAQ:RLMD – Get Rating) to report earnings of ($1.21) per share for the current quarter, according to Zacks. Zero analysts have issued estimates for Relmada Therapeutics’ earnings, with estimates ranging from ($1.26) to ($1.12). Relmada Therapeutics posted earnings per share of ($1.34) in the same quarter last year, which suggests a positive year over year growth rate of 9.7%. The business is scheduled to issue its next earnings results on Monday, January 1st.
According to Zacks, analysts expect that Relmada Therapeutics will report full year earnings of ($5.15) per share for the current year, with EPS estimates ranging from ($5.25) to ($4.97). For the next year, analysts expect that the business will post earnings of ($3.77) per share, with EPS estimates ranging from ($5.67) to ($2.50). Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that that provide coverage for Relmada Therapeutics.
Relmada Therapeutics (NASDAQ:RLMD – Get Rating) last announced its earnings results on Wednesday, March 23rd. The company reported ($1.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.60) by ($0.20). During the same period in the prior year, the firm posted ($1.28) EPS.
In related news, Director Paul Edward Kelly sold 10,000 shares of the stock in a transaction dated Monday, April 4th. The shares were sold at an average price of $30.04, for a total value of $300,400.00. Following the completion of the transaction, the director now directly owns 187,295 shares of the company’s stock, valued at $5,626,341.80. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 11.00% of the company’s stock.
A number of institutional investors and hedge funds have recently made changes to their positions in RLMD. Point72 Asset Management L.P. grew its holdings in Relmada Therapeutics by 330.1% in the fourth quarter. Point72 Asset Management L.P. now owns 946,313 shares of the company’s stock worth $21,320,000 after purchasing an additional 726,313 shares during the period. Morgan Stanley grew its holdings in shares of Relmada Therapeutics by 1,604.7% during the third quarter. Morgan Stanley now owns 449,341 shares of the company’s stock valued at $11,777,000 after buying an additional 422,982 shares during the last quarter. Millennium Management LLC grew its holdings in shares of Relmada Therapeutics by 1,468.7% during the third quarter. Millennium Management LLC now owns 254,580 shares of the company’s stock valued at $6,673,000 after buying an additional 238,351 shares during the last quarter. Altium Capital Management LP purchased a new stake in shares of Relmada Therapeutics during the fourth quarter valued at approximately $4,641,000. Finally, BlackRock Inc. grew its holdings in shares of Relmada Therapeutics by 14.5% during the fourth quarter. BlackRock Inc. now owns 1,385,235 shares of the company’s stock valued at $31,211,000 after buying an additional 174,994 shares during the last quarter. Institutional investors and hedge funds own 76.11% of the company’s stock.
Shares of NASDAQ:RLMD opened at $22.40 on Tuesday. Relmada Therapeutics has a 52-week low of $16.23 and a 52-week high of $39.66. The firm has a fifty day moving average of $24.53 and a 200 day moving average of $21.94. The firm has a market capitalization of $659.30 million, a PE ratio of -3.14 and a beta of 0.51.
Relmada Therapeutics Company Profile (Get Rating)
Relmada Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults.
- Get a free copy of the StockNews.com research report on Relmada Therapeutics (RLMD)
- Kellogg Company Flexes Pricing Power, Shares Move Higher
- Peak Growth Is Over For Etsy
- Uber Fails To Impress
- World Wresting Entertainment Stock is Hulking Up
- High-Yield Weyco Group Returns To Reasonable Levels
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Relmada Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relmada Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.